ANVS
Annovis Bio, Inc.
NYSE · Healthcare · Biotechnology · US
$1.14
+3.64%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.12
From 52W high−77.65%
Volume676926.00
Market cap$48.65M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.12
From 52W high
−77.65%
Volume
676926.00
Market cap
$48.65M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
—
RSI (14)
27.6
MomentumView details →
1D Return
+3.64%
YTD Return
−67.63%
SummaryUpdated Jun 1, 2026
Annovis Bio, Inc. (NASDAQ:ANVS) is a clinical-stage biotechnology company founded in 2008 and headquartered in Berwyn, Pennsylvania. The company went public in January 2020 and focuses on developing novel drug treatments for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Annovis operates as a drug platform company, meaning it develops a portfolio of compounds that can potentially treat multiple neurological conditions through similar mechanisms of action.
Similar companies
Latest newsMore news →
ANNOVIS BIO announced that its Phase 3 clinical trial for Alzheimer's disease has completed enrollment of all subjects, with key data and regulatory submission expected in 2027.26d agoAnnovis Bio, Inc. reported its financial results for the second quarter ended June 30, 2026.37d agoAnnovis Bio reached full enrollment in its pivotal Phase 3 trial of buntanetap for early Alzheimer's disease.75d ago